Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
Zoe MoodieErica Andersen-NissenNicole A GrunenbergOne B DintweFaatima Laher OmarJia J KeeLinda-Gail BekkerFatima LaherNivashnee NaickerIlesh V JaniNyaradzo M MgodiPortia HunidzariraModulakgota SebeMaurine D MinerLaura L PolakowskiShelly RamirezMichelle NebergallSimbarashe TakuvaLerato SikhosanaJack HeptinstallKelly E SeatonStephen De RosaCarlos A DiazgranadosMarguerite KoutsoukosOlivier Van Der MeerenSusan W BarnettNiranjan Kanesa-ThasanJames G KublinGeorgia D TomarasM Juliana McElrathLawrence CoreyKathryn Therese MngadiPaul Goepfertnull nullPublished in: PLoS medicine (2024)
HVTN 107 was registered with the South African National Clinical Trials Registry (DOH-27-0715-4894) and ClinicalTrials.gov (NCT03284710).